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Jiandie D. Lin 1,*ABSTRACT
Objective: Brown and white adipose tissue exerts pleiotropic effects on systemic energy metabolism in part by releasing endocrine factors.
Neuregulin 4 (Nrg4) was recently identified as a brown fat-enriched secreted factor that ameliorates diet-induced metabolic disorders, including
insulin resistance and hepatic steatosis. However, the physiological mechanisms through which Nrg4 regulates energy balance and glucose and
lipid metabolism remain incompletely understood. The aims of the current study were: i) to investigate the regulation of adipose Nrg4 expression
during obesity and the physiological signals involved, ii) to elucidate the mechanisms underlying Nrg4 regulation of energy balance and glucose
and lipid metabolism, and iii) to explore whether Nrg4 regulates adipose tissue secretome gene expression and adipokine secretion.
Methods: We examined the correlation of adipose Nrg4 expression with obesity in a cohort of diet-induced obese mice and investigated the
upstream signals that regulate Nrg4 expression. We performed metabolic cage and hyperinsulinemic-euglycemic clamp studies in Nrg4
transgenic mice to dissect the metabolic pathways regulated by Nrg4. We investigated how Nrg4 regulates hepatic lipid metabolism in the fasting
state and explored the effects of Nrg4 on adipose tissue gene expression, particularly those encoding secreted factors.
Results: Adipose Nrg4 expression is inversely correlated with adiposity and regulated by pro-inflammatory and anti-inflammatory signaling.
Transgenic expression of Nrg4 increases energy expenditure and augments whole body glucose metabolism. Nrg4 protects mice from diet-
induced hepatic steatosis in part through activation of hepatic fatty acid oxidation and ketogenesis. Finally, Nrg4 promotes a healthy adipo-
kine profile during obesity.
Conclusions: Nrg4 exerts pleiotropic beneficial effects on energy balance and glucose and lipid metabolism to ameliorate obesity-associated
metabolic disorders. Biologic therapeutics based on Nrg4 may improve both type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) in
patients.
 2017 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Adipose tissue is central to systemic energy balance and metabolic
homeostasis. White adipose tissue (WAT) stores lipids and commu-
nicates with the central nervous system and other peripheral tissues by
secreting a number of important endocrine hormones [1e3]. WAT also
serves as a major site for the integration of immune and metabolic
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in defense against cold and energy excess [7e9]. Secreted factors are
important regulators of carbohydrate and lipid metabolism and sys-
temic energy homeostasis. Adipose tissue hormones, such as leptin
and adiponectin [1e3], gut-derived fibroblast growth factors [10,11],
and myokines [12] participate in nutrient sensing and coordinate key
aspects of nutrient and energy metabolism. By integrating mouse
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Original Articleenriched secreted factors was identified [13]. Among these, Neu-
regulin 4 (Nrg4) emerged as a BAT-enriched endocrine factor that
exerts robust effects on hepatic lipid metabolism and systemic ho-
meostasis. Brown fat is also known to release factors that exhibit a
wider expression profile, such as Vascular endothelial growth factor a
(VEGFa), Fibroblast growth factor 21 (FGF21), Interleukin-6 (IL-6), and
Bone morphogenetic proteins (BMPs) [14,15]. As such, brown fat is
emerging as a source of endocrine factors that exerts powerful
metabolic effects beyond UCP1-mediated thermogenesis [14,15].
Nrg4 expression is more abundant in brown fat than white fat; a similar
pattern was observed in a recent study on differential gene expression
in adipose tissue [16]. Despite its enrichment in brown fat, Nrg4
expression is readily detectable in white fat, which likely provides a
significant source of total Nrg4 in circulation given its relatively large
mass. An intriguing aspect of Nrg4 regulation is that its expression in
WAT is markedly downregulated in mouse and human obesity [13].
These findings raise the possibility that obesity is associated with a
functional deficit of Nrg4 that exacerbates the progression of metabolic
disorders. In support of this, mice lacking Nrg4 developed more severe
insulin resistance and hepatic steatosis following high-fat feeding,
whereas fat-specific transgenic expression of Nrg4 significantly im-
proves metabolic parameters and ameliorates diet-induced disruption
of homeostasis. At the molecular level, Nrg4 transduces signals
through the ErbB4 and ErbB3 receptor tyrosine kinases and elicits an
inhibitory effect on hepatic lipogenesis. Despite these intriguing find-
ings, the physiological mechanisms through which Nrg4 modulates
energy balance and glucose and lipid metabolism remain incompletely
understood. In this study, we performed metabolic cage and
hyperinsulinemic-euglycemic clamp studies and revealed a surpris-
ingly pleiotropic effect of Nrg4 signaling on key aspects of systemic
energy and glucose metabolism. We identified hepatic fatty acid
oxidation and ketogenesis as a new metabolic target of endocrine
signaling by Nrg4. Finally, we found that Nrg4 promotes a beneficial
adipokine profile during obesity. Together, this work provides impor-
tant insights into the physiological actions of Nrg4 that contribute to its
beneficial effects on metabolic homeostasis.
2. MATERIALS AND METHODS
2.1. Mouse studies
All mouse studies were performed according to procedures approved
by the University Committee on Use and Care of Animals at the
University of Michigan. The generation of Nrg4 transgenic and
knockout mice was described previously [13]. Mice were maintained
under 12/12 h light/dark cycles with free access to food and water.
Teklad 5001 laboratory diet was used as a standard chow. For HFD
feeding, mice were fed a diet containing 60% of calories from fat
(D12492, Research Diets). Metabolic cage study was performed at
the University of Michigan Animal Phenotyping Core using CLAMS
(Columbus Instruments). The measurements were carried out for a
total of 72 h. Energy expenditure was calculated as the value cor-
responding to 3.91VO2 þ 1.1VCO2. Body fat and lean mass were
measured using an NMR analyzer (Minispec LF90II, Bruker Optics).
Plasma concentrations of TAG, total cholesterol, NEFA, and b-
hydroxybutyrate were measured using commercial assay kits (Stanbio
Laboratory). Plasma insulin and leptin concentrations were measured
using ELISA (Crystal Chem).
2.2. Hyperinsulinemic-euglycemic clamp
Mice were fasted overnight (approximately 15 h), and a 2-h
hyperinsulinemic-euglycemic clamp was conducted in awake mice864 MOLECULAR METABOLISM 6 (2017) 863e872  2017 The Authors. Published by Elsevwith a primed and continuous infusion of human insulin (150 mU/kg
body weight priming followed by 2.5 mU/kg/min; Novolin, Novo Nor-
disk, Plainsboro, NJ) [17]. To maintain euglycemia, 20% glucose was
infused at variable rates during clamps. Whole body glucose turnover
was assessed with a continuous infusion of [3-3H]glucose (Perki-
nElmer, Waltham, MA), and 2-deoxy-D-[1-14C]glucose (2-[14C]DG)
was administered as a bolus (10 mCi) at 75 min after the start of
clamps to measure insulin-stimulated glucose uptake in individual
organs. At the end of the clamps, mice were anesthetized, and tissues
were taken for biochemical analysis as previously described [17].
2.3. Adipocyte studies
3T3-L1 preadipocytes were cultured in DMEM with 10% bovine growth
serum until two days post confluence (denoted as day 0). Differenti-
ation was induced by adding a cocktail containing 0.5 mM IBMX, 1 mM
dexamethasone, and 1 mg/mL insulin to DMEM supplemented with
10% FBS. Three days after induction, cells were cultured in DMEM
containing 10% FBS plus 1 mg/mL of insulin for two more days fol-
lowed by maintenance in DMEM supplemented with 10% FBS.
Differentiated adipocytes were treated with TNFa, VIII compound,
Rosiglitazone, GW9508 and DHA for 17 h in maintenance media before
RNA isolation and RT-qPCR analysis.
2.4. qPCR and immunoblotting analyses
RT-qPCR analysis of gene expression was performed as previously
described [18]. Briefly, total adipocyte and liver RNA was extracted
using TRIzol method. Total RNA from eWAT and BAT was isolated using
PureLink RNA isolation kit (ThermoFisher). For RT-qPCR, 2 mg of total
RNA was reverse-transcribed using MMLV-RT followed by qPCR using
SYBR Green (Life Technologies). Relative mRNA expression was
normalized to the levels of ribosomal protein 36B4. Total eWAT lysates
were prepared by tissue homogenization in a lysis buffer containing
50 mM Tris (pH 7.5), 150 mM NaCl, 5 mM NaF, 25 mM b-glycer-
olphosphate, 1 mM sodium orthovanadate, 10% glycerol, 1% tritonX-
100, 1 mM dithiothreitol, and freshly added protease inhibitors.
Immunoblotting was performed using specific antibodies against
adipsin (Santa Cruz Biotech, sc-50419).
2.5. Microarray analysis
Gene expression profiling was performed using Mouse Gene ST 2.1
array. We used a cutoff of normalized array values (log2-transformed
values > 7.0) for adipose tissue transcripts. Pathway enrichment
analysis was performed using the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID, available at http://david.abcc.
ncifcrf.gov). Adipose tissue gene expression was visualized using
TreeView.
2.6. Stimulated Raman scattering (SRS) microscopy
SRS microscopy was used to evaluate lipid accumulation in hepato-
cytes as previously described [19]. Briefly, liver specimens were
sectioned into a series of 50 mm thickness tissue slices by a vibratome.
Single slice was sandwiched between two coverslips for SRS imaging
of lipids with the beating frequency tuned to 2850 cm1.
2.7. Hepatic lipid and CoA analyses
Hepatic lipids were extracted using Bligh-Dyer method in the presence
of an internal standard (T21:0 TAG, 10 nmol/mg protein) and separated
on silica gel 60A plates that were developed with a nonpolar acidic
mobile phase (70:30:1, v/v/v, hexane/ethyl ether/acetic acid). Fatty
acid profiling was performed using procedure described previously
[13]. CoA ester levels were assessed in perchloric acid extracted heartier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tissue using a high-performance liquid chromatography procedure
described previously [20].
2.8. Statistical analysis
Statistical analysis was performed using GraphPad Prism 7. Statistical
differences were evaluated using two-tailed unpaired Student’s t-test
or one-way analysis of variance (ANOVA) with appropriate post hoc
analyses. A p value of less than 0.05 (*p < 0.05, **p < 0.01, and
***p < 0.001) was considered statistically significant. Statistical
methods and corresponding p values for data shown in each panel
were included in figure legends.
3. RESULTS
3.1. Regulation of adipose Nrg4 expression in obesity
Nrg4 was identified as a brown fat-enriched endocrine factor that
improves obesity-associated insulin resistance and hepatic steatosis
[13]. However, the physiological mechanisms underlying the metabolic
effects of Nrg4 on glucose and lipid metabolism and energy balance
remain incompletely understood. To address this, we first examined
adipose tissue expression of Nrg4 in high-fat diet (HFD) induced
obesity. Wild type C57BL/6J mice gained various amounts of body
weight following two months of high-fat feeding. Nrg4 mRNA levels in
epididymal white adipose tissue (eWAT), but not BAT, exhibited aFigure 1: Regulation of adipose Nrg4 expression. (A) Correlation of eWAT Nrg4, Ccl2, a
(B) Correlation of BAT Nrg4 expression with body weight. (C) Correlation of eWAT Nrg4 m
qPCR analysis of Nrg4 expression in 3T3-L1 adipocytes treated with vehicle () or 20 nM T
3T3-L1 adipocytes treated with vehicle or TNFa without or with 10 mM rosiglitazone (R
GW9508, or DHA at indicated concentrations (mM) for 17 h. Data represent mean  sd.
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B). The profile of Nrg4 expression was remarkably similar to that of
adiponectin, which has been shown to decrease in eWAT during
obesity [1]. On the contrary, the expression of Ccl2, a chemotactic
cytokine for macrophages, showed a strong positive correlation with
body weight. We further examined the association between eWAT Nrg4
expression and blood glucose and plasma insulin concentrations. As
shown in Figure 1C, there was a strong inverse correlation of Nrg4
mRNA levels with blood glucose and plasma insulin concentrations.
Mice exhibiting low adipose Nrg4 expression tended to have more
severe HFD-induced hyperglycemia and hyperinsulinemia, suggesting
that reduced Nrg4 expression may be causally linked to insulin
resistance.
Obesity is associated with chronic low-grade inflammation in WAT that
is characterized by increased pro-inflammatory cytokine signaling. We
next examined how pro-inflammatory and anti-inflammatory stimuli
modulate Nrg4 expression in cultured adipocytes. Treatment of
differentiated 3T3-L1 adipocytes with TNFa, a prototypical pro-
inflammatory cytokine, significantly decreased Nrg4 expression
through a mechanism that require NF-kB activation (Figure 1D).
Addition of IKK2 inhibitor VIII, a compound that blocks NF-kB activation,
abolished the inhibition of Nrg4 expression in response to TNFa. The
inhibitory effect of TNFa on Nrg4 expression was also reversed by
rosiglitazone (Figure 1E), which exerts powerful anti-inflammatorynd Adipoq mRNA levels with body weight and eWAT mass in mice fed HFD for 8 weeks.
RNA levels with blood glucose and plasma insulin concentrations in HFD-fed mice. (D)
NFa without or with 2 mM inhibitor VIII for 17 h. (E) qPCR analysis of Nrg4 expression in
osi). (F) qPCR analysis of Nrg4 expression in 3T3-L1 adipocytes treated with vehicle,
*p < 0.01, vs. vehicle; one-way ANOVA.
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protein coupled receptor 120 (GPR120) was recently identified as a
receptor for fatty acid ligands, particularly the unsaturated fatty acids
such as docosahexaenoic acid (DHA) [22,23]. Interestingly, treatment
of 3T3-L1 adipocytes with DHA or the synthetic GPR120 agonist
GW9508 resulted in robust induction of Nrg4 expression (Figure 1F).
These results indicate that pro-inflammatory and anti-inflammatory
signals exert opposite effects on Nrg4 expression in adipocytes.
Further, adipose tissue inflammation is likely a driving force in obesity-
associated decrease of Nrg4 expression in adipose tissue.
3.2. Nrg4 protects mice from diet-induced obesity by increasing
energy expenditure
We previously demonstrated that fat-specific transgenic expression of
Nrg4 in adipose tissue ameliorates diet-induced obesity and metabolic
disorders [13]. Body composition analysis indicated that, compared to
wild type (WT) littermate controls, Nrg4 transgenic (Tg) mice had
significantly less fat mass following seven weeks of high-fat feeding
(Figure 2A). Whole body lean mass appeared similar between two
groups. Plasma leptin levels were lower in Tg mice than control,
suggesting that leptin sensitivity is improved in Tg group (Figure 2B).
To assess how Nrg4 affects diet-induced weight gain, we performed
metabolic cage studies in HFD-fed control and transgenic mice using
Comprehensive Laboratory Animal Monitoring System (CLAMS) to
assess energy balance. Oxygen consumption rate and energy expen-
diture were significantly elevated in Nrg4 transgenic mice during both
dark and light phases (Figure 2C, D). While food intake was similar in
the dark phase, it was moderately higher in Tg mice during the light
phase (Figure 2E). Transgenic mice also exhibited increased locomotor
activity during the dark phase (Figure 2F). These results strongly
suggest that transgenic elevation of Nrg4 levels protects mice from
diet-induced obesity by stimulating fuel oxidation and increasing en-
ergy expenditure.Figure 2: Body composition analysis and metabolic cage study. (A) Body weight, fat m
weeks. (B) Plasma leptin concentrations. (C) Oxygen consumption rate. Averaged oxyg
expenditure. (E) Food intake. (F) Total activity counts. Data represent mean  sem. *p <
866 MOLECULAR METABOLISM 6 (2017) 863e872  2017 The Authors. Published by Elsev3.3. Nrg4 improves insulin sensitivity by enhancing peripheral
glucose metabolism
We next determined how Nrg4 regulates whole body glucose meta-
bolism using hyperinsulinemic-euglycemic clamp in awake mice after
ten weeks of high-fat feeding. Consistent with improved glucose ho-
meostasis, Nrg4 transgenic mice required a higher glucose infusion
rate to maintain euglycemia during clamps as compared to WT mice
(Figure 3A). Whole body glucose turnover and glycolysis were signif-
icantly increased in Tg mice, whereas clamp hepatic glucose pro-
duction did not differ between Tg and WT mice (Figure 3A). These data
indicate that higher glucose infusion rate in Tg mice is largely due to
increased glucose metabolism in peripheral organs, but not in liver.
Measurements of glucose uptake in individual tissues confirmed that
insulin-stimulated glucose uptake in skeletal muscle was enhanced in
Tg mice (Figure 3B). In contrast, glucose uptake in white fat and brown
fat remained largely unaltered by transgenic expression of Nrg4 in
adipocytes. Previous studies demonstrated that Nrg4/ErbB4 signaling
attenuates induction of hepatic lipogenesis in response to HFD feeding
[13]. Consistent with this, measurement of 3H-glucose incorporation in
liver triglycerides (TAG) revealed that hepatic lipogenic activity was
significantly reduced in Nrg4 transgenic mice (Figure 3C). These re-
sults illustrate that Nrg4 exerts a pleiotropic effect on pathways
contributing to systemic glucose homeostasis. Increased glucose up-
take and utilization likely plays a dominant role in whole body glucose
metabolism despite reduced flux of carbohydrates through hepatic
lipogenic pathway.
3.4. Nrg4 induces a catabolic metabolic state in the liver
Nrg4 transgenic mice developed less severe hepatic steatosis than
control following high-fat feeding, whereas mice lacking Nrg4 had
more pronounced hepatic fat accumulation. This phenotype is at least
in part due to the inhibitory effect of Nrg4/ErbB4 signaling on hepatic
lipogenesis. However, whether Nrg4 regulates fatty acid oxidation inass, and lean mass in WT (open, n ¼ 8) and Nrg4 Tg (brown, n ¼ 7) mice fed HFD for 7
en consumption rate in dark and light phases is indicated on the right. (D) Energy
0.05, **p < 0.01, ***p < 0.001, WT vs. Tg; two-tailed unpaired Student’s t-test.
ier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 3: Hyperinsulinemic-euglycemic clamp study. (A) Glucose infusion rate, whole body glucose turnover, whole body glycolysis, and hepatic glucose production during
clamp in WT (open, n ¼ 9) and Tg (brown, n ¼ 8) mice fed HFD for ten weeks. (B) Insulin-stimulated glucose uptake in skeletal muscle, WAT, and BAT. (C) Incorporation of 3H-
labeled glucose into liver lipids. Data represent mean  sem. *p < 0.05, WT vs. Tg; two-tailed unpaired Student’s t-test.the liver has not been examined. Interestingly, Nrg4 transgenic mice
exhibited a significantly higher concentration of b-hydroxybutyrate in
plasma following overnight fasting (Figure 4A), suggesting that Nrg4
may promote hepatic fatty acid oxidation and ketone production during
starvation. Plasma TAG concentration was significantly lower in TgFigure 4: Effects of Nrg4 transgenic expression on lipid metabolism. (A) Plasma lipid
overnight starvation. (B) SRS imaging of liver sections. Scale bar ¼ 50 mm. (C) Concentrat
two-tailed unpaired Student’s t-test.
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and non-esterified fatty acids (NEFA) were similar between two groups.
We performed Stimulated Raman Scattering (SRS) microscopy, a label-
free method to visualize intracellular lipid droplets [19], to assess fat
accumulation in control and Tg mice following high-fat feeding. Weconcentrations in HFD-fed WT (open, n ¼ 10) and Tg (brown, n ¼ 9) mice following
ion of CoA metabolites in the liver. Data represent mean  sem. *p < 0.05, WT vs. Tg;
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consistent with ameliorated hepatic steatosis (Figure 4B). In contrast,
liver glycogen content was low following overnight fasting and did not
exhibit significant difference between two groups (data not shown).
Co-enzyme A (CoA) is a coenzyme that plays a central role in lipid
metabolism. Measurements of CoA levels indicated that the concen-
trations of CoA and acetyl-CoA, but not succinyl-CoA, were significantly
elevated in Tg liver (Figure 4C), likely contributing to increased flux of
fatty acid b-oxidation and ketogenesis. Surprisingly, malonyl-CoA
levels were also elevated in Nrg4 Tg livers, likely due to substrate
accumulation as a result of reduced flux through the de novo lipogenic
pathway.
We next determined whether Nrg4 deficiency impairs hepatic fatty acid
oxidation in the fasting state. Consistent with transgenic studies,
plasma concentration of b-hydroxybutyrate was significantly lower in
Nrg4 knockout (KO) mice following overnight starvation (Figure 5A).
While plasma TAG and NEFA levels remained similar, total cholesterol
level was moderately elevated in KO group. The differential effects of
Nrg4 transgenic overexpression and deficiency on plasma TAG and
cholesterol levels suggest that distinct compensatory mechanisms
may be activated in gain- and loss-of-function mouse models. SRS
microscopy revealed that Nrg4 KO mice developed more severe he-
patic steatosis following high-fat feeding, as shown by the presence of
large lipid droplets in hepatocytes (Figure 5B). Accordingly, fatty acid
profiling of liver lipids indicated that the levels of major fatty acid
species, including palmitic acid (C16:0), linoleic acid (C18:2n-6), andFigure 5: Effects of Nrg4 deficiency on lipid metabolism. (A) Plasma lipid concentrati
starvation. (B) SRS imaging of liver sections. Scale bar ¼ 50 mm. (C) Fatty acid profiling ana
KO; two-tailed unpaired Student’s t-test.
868 MOLECULAR METABOLISM 6 (2017) 863e872  2017 The Authors. Published by Elsevoleic acid (C18:1n-9), were significantly elevated in Nrg4 KO mouse
liver (Figure 5C). These results suggest that Nrg4 may exert its effects
on hepatic fat content by reducing lipogenesis and augmenting fatty
acid oxidation.
3.5. Regulation of adipose tissue gene expression by Nrg4
White fat plays a central role in the regulation of fuel storage and also
serves as an important source of endocrine hormones. In addition,
adipose tissue inflammation has been causally linked to obesity-
associated metabolic disorders. Previous Nrg4 binding studies were
inconclusive for adipose tissue due to poor preservation of histology on
frozen fat sections [13]. Despite abundant Nrg4 expression in adipose
tissue, it remains unknown whether Nrg4 may directly or indirectly
regulate adipose tissue function. To test this, we performed gene
profiling in eWAT from HFD-fed WT and Tg mice using microarray. We
identified two clusters of genes that exhibit significant downregulation
(81 genes) or upregulation (73 genes) in response to transgenic
expression of Nrg4 (Figure 6A and Supplementary Table S1). Pathway
analysis of these two clusters indicated that genes downregulated by
Nrg4 were enriched for those involved in immune and inflammatory
response. Genes encoding proteins predicted to contain
immunoglobulin-like domain and secreted glycoproteins were also
enriched in this cluster. The upregulated cluster was enriched for
genes involved in mitochondrial function and energy metabolism.
QPCR analysis indicated that the expression of several genes involved
in inflammatory signaling, including Ccl4, Tnfa, Cd68, Il10, and Emr1,ons in HFD-fed WT (open, n ¼ 9) and Nrg4 KO (blue, n ¼ 8) mice following overnight
lysis of total liver lipids. Data represent mean  sem. *p < 0.05, ***p < 0.001, WT vs.
ier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: Regulation of eWAT gene expression by Nrg4. (A) Two clusters of genes downregulated (I) and upregulated (II) by over 1.6-fold in eWAT from Nrg4 Tg mice (top).
Enrichment scores of biological processes for the genes in two clusters (bottom). (B) qPCR analysis of eWAT gene expression in HFD-fed WT (open, n ¼ 10) and Nrg4 transgenic
(brown, n ¼ 9) mice. (C) qPCR analysis of eWAT gene expression in HFD-fed WT (open, n ¼ 9) and Nrg4 KO (blue, n ¼ 8) mice. Data represent mean  sem. *p < 0.05, vs. WT;
two-tailed unpaired Student’s t-test.
Figure 7: Regulation of eWAT secretome by Nrg4. (A) Reciprocal regulation of secreted factor gene expression in eWAT from Nrg4 transgenic and knockout mice. Shown are
genes that exhibit an increase or decrease in expression by over 1.4-fold based on microarray expression values. (B) qPCR analyses of adipsin gene expression in eWAT from a
cohort of HFD-fed WT (open, n ¼ 10) and Nrg4 Tg (brown, n ¼ 9) mice and a cohort of WT (open, n ¼ 9) and Nrg4 KO (blue, n ¼ 8) mice. Data represent mean  sem. *p < 0.05,
vs. WT; two-tailed unpaired Student’s t-test. (C) Immunoblotting of plasma samples from chow or HFD-fed WT and Tg mice. (D) Immunoblotting of plasma samples from chow or
HFD-fed WT and Nrg4 KO mice.
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Figure 8: A model depicting the pleiotropic action of Nrg4 and its role in
metabolic homeostasis. Nrg4 expression is repressed by pro-inflammatory signaling
in white adipose tissue. Nrg4 preserves insulin sensitivity and ameliorates NAFLD by
attenuating hepatic lipogenesis, augmenting fuel oxidation and energy expenditure, and
maintaining a healthy adipokine profile.
Original Articlewas significantly lower in transgenic eWAT (Figure 6B). On the con-
trary, mRNA expression for inflammation-associated genes was
elevated in eWAT from HFD-fed Nrg4 KO mice (Figure 6C). The
expression of adipogenic genes (Pparg, Fabp4) remained similar.
These results are consistent with recent studies that demonstrate anti-
inflammatory activities of Nrg4/ErbB4 signaling in adipose tissue and
colon [24,25].
3.6. Nrg4 promotes a healthy profile of adipokine secretion
Adipose tissue releases diverse secreted factors that act locally or
function as endocrine regulators. To determine whether Nrg4 plays a
role in modulating the adipocyte secretome, we examined microarray
expression levels of the genes that are included in the mouse
secretome list and predicted to encode secreted proteins. We
identified a list of genes encoding secreted proteins that exhibited
transcriptional regulation in Nrg4 transgenic and knockout mouse
eWAT in the opposite manner (Figure 7A). Heat map representation
revealed that transgenic expression of Nrg4 increased mRNA
expression of several adipokines that have been demonstrated to
exert beneficial metabolic effects, including Adipsin (Complement
factor d, Cfd), Adiponectin, and Vascular endothelial growth factor a
(Vegfa). Adipsin has been shown to improve b cell function in dia-
betes and its expression is downregulated in obesity [26,27]. While
adiponectin exerts its beneficial effects on diverse tissues including
skeletal muscle and the liver [28,29], VEGFa appears to improve
metabolic physiology by acting locally to enhance adipose tissue
vascularization and function [30,31]. The expression of genes870 MOLECULAR METABOLISM 6 (2017) 863e872  2017 The Authors. Published by Elsevinvolved in the classical complement activation pathway, including
C1qa, C1qb, and C1qc, were downregulated in eWAT from Nrg4
transgenic mice. Remarkably, Nrg4 deficiency resulted in elevated
expression for these factors. C1qa expression has been shown to be
elevated in visceral adipose tissue from obese patients and its
deficiency protects mice from HFD-induced insulin resistance
[32,33]. We confirmed the expression of adipsin using qPCR
(Figure 7B). Further, while plasma adipsin levels were similar be-
tween chow-fed WT and Tg mice, transgenic expression of Nrg4
greatly increased adipsin levels in circulation following high-fat
feeding (Figure 7C). Similarly, no difference was observed between
WT and KO mice under chow-fed condition. Nrg4 deficiency resulted
in lower adipsin levels in diet-induced obese mice, but not chow-fed
lean mice (Figure 7D). These results strongly suggest that Nrg4
promotes a healthy adipokine profile that likely contributes to the
amelioration of obesity-associated metabolic disorders.
4. DISCUSSION
Adipose tissue releases a plethora of secreted factors that act locally or
on distal tissues to influence metabolic physiology. Nrg4 was recently
identified as a brown fat-enriched endocrine factor that ameliorates
HFD-induced insulin resistance and hepatic steatosis [13]. Despite
these intriguing findings, the physiological mechanisms through which
Nrg4 regulates systemic energy balance and glucose and lipid meta-
bolism have not been elucidated. In this study, we provide the novel
demonstration that Nrg4 reduces HFD-induced weight gain in mice by
enhancing basal metabolic rate and energy expenditure. Transgenic
activation of Nrg4 signaling resulted in increased whole body glucose
turnover and glycolysis that was in part due to augmented skeletal
muscle glucose utilization. We also identified hepatic fatty acid b-
oxidation and ketogenesis as a new downstream target of Ngr4 in
hepatocytes, likely contributing to the protective effects of Nrg4 on
hepatic steatosis. Finally, Nrg4 promotes a beneficial adipokine profile
in white fat that was associated with reduced expression of genes
involved in inflammatory response. This study illustrates the surpris-
ingly pleiotropic effects of Nrg4 on energy and nutrient metabolism
(Figure 8).
Neuregulin proteins belong to a small family of extracellular ligands
that includes Nrg1, Nrg2, Nrg3, and Nrg4 [34e36]. Among these,
Nrg1, 2, and 3 are highly expressed in the central nervous system.
Nrg4 is the only member that exhibits high levels of expression in
brown and white fat. Remarkably, Nrg4 mRNA expression in white
adipose tissue inversely correlates with adiposity in both rodents and
humans [13]. These observations strongly suggest that defective Nrg4
secretion may lead to a hormonal insufficiency during obesity that
exacerbates the progression of metabolic disorders. In support of this,
plasma Nrg4 levels were inversely associated with the risk for meta-
bolic syndrome in obese Chinese adults [37]. While adipocyte Nrg4
expression is suppressed by pro-inflammatory cytokines, anti-
inflammatory agents such as rosiglitazone and agonists for GPR120
exert an opposite effect. These results illustrate that the balance be-
tween pro-inflammatory and anti-inflammatory signals is likely a key
driver of adipose tissue Nrg4 expression.
Because Nrg4 binding appears to be restricted to hepatocytes, the
pleiotropic effects of Nrg4 on glucose and lipid metabolism came
somewhat as a surprise. It is likely that these metabolic effects are due
to a combination of direct Nrg4 action and secondary consequences of
Nrg4 manipulations. For example, adipose tissue expresses very low
levels of ErbB3 and ErbB4, two receptors that mediate Nrg4 signaling.
It is possible that the shift in adipokine profile in response to transgenicier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
expression and deficiency of Nrg4 occurs as a result of Nrg4 signaling
in other tissues. The molecular nature of such a regulatory circuitry
remains unknown.
Previous studies demonstrated that ErbB receptors are expressed in
skeletal myocytes and that a fragment corresponding to the EGF-like
domain of Nrg1 was capable of stimulating glucose uptake in
cultured C2C12 myotubes [38e40]. Nrg1 treatment improved whole
body glucose metabolism in db/db mice and diabetic rats [41,42].
Whether Nrg4 may act directly on skeletal muscle to promote glucose
uptake and utilization remains an important question to be addressed
in future studies. Beyond peripheral tissues, ErbB4 is highly expressed
in the central nervous system, including the hypothalamus [43e45].
Importantly, ErbB4 polymorphism was recently shown to strongly
associate with body mass index in a genome-wide association study
[46]. Because Nrg4 transgenic mice exhibited reduced fat mass and
elevated energy expenditure, our findings raise the possibility that
Nrg4/ErbB4 signaling may be a genetic factor for human obesity and its
associated metabolic disorders. Given the pleiotropic metabolic ben-
efits elicited by Nrg4, biologic therapeutics targeting this pathway may
provide an effective treatment that simultaneously targets type 2
diabetes and NAFLD in patients.ACKNOWLEDGMENTS
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